| HOME >> BIOLOGY >> TECHNOLOGY |
A potential investor has agreed in principle to lead the fundraising efforts subject to finalization of the deal structure.
Semen Sexing Technology (SST)
In the SST program, Microbix focused on strengthening its intellectual property position. "We concluded the research phase of the program in the second quarter," said Mr. Gastle. "The results led to a conclusion which brings the market opportunity closer with more certainty and also provides a significant competitive advantage over existing technology. It will give the Company a strong patent position in a $ 3 billion artificial insemination market which has no regulatory barrier to entry." The Company is currently evaluating non-dilutive ways to advance the product.
Urokinase
The Company acquired all Urokinase assets from ImaRx Therapeutics, Inc. of Tucson, Arizona, (Nasdaq: IMRX) in September 2008. These assets included ImaRx' remaining Urokinase inventory as well as the regulatory file for the product (formerly known as Abbokinase(R), now rebranded as Kinlytic(R)), key raw materials for Urokinase manufacturing, and the corresponding sales and marketing infrastructure.
The anticipated launch of the drug Kinlytic has been delayed due to the ongoing review by the FDA of the Company's request for the release of this Urokinase product for distribution in the US market. The company is preparing to file an appeal that will be submitted in the third quarter. "There are no problems with the safety and efficacy of this drug. Concerned physicians are asking for Urokinase supply on a daily basis," Mr. Gastle explained. Microbix is one of many drug companies that are experiencing delays at the FDA today and continues to press matters with the agency," said Mr. Gastle. "We are optimistic that ultimately we will reach the market" he said.
Ot
'/>"/>
| SOURCE Microbix Biosystems Inc. Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
2. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
3. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
4. Microbix Announces A New Technology Platform For The SST Project
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
7. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
8. Kline Study: Better Brushing Habits Boost European Oral Care Sales
9. BioElectronics Corporation Announces Singapore and Malaysia Sales
10. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
11. AMDLs Jade Pharmaceutical Subsidiary Announces New Product Strategy; Six New Products, Including One With Sales Projected at Upwards of $10 Million, Under Development
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |